Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FLT3-TKD mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

Related tests:

LeukoStrat® CDx FLT3 Mutation Assay (6)

LeukoStrat® CDx FLT3 Mutation Assay (6)

FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2	gilteritinib Sensitive: A2 - Guideline gilteritinib Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2	cytarabine + midostaurin + daunorubicin Sensitive: A2 - Guideline cytarabine + midostaurin + daunorubicin Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B	venetoclax Sensitive: B - Late Trials venetoclax Sensitive : B
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3	venetoclax + gilteritinib Sensitive: C3 – Early Trials venetoclax + gilteritinib Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	sorafenib + gilteritinib Sensitive: C3 – Early Trials sorafenib + gilteritinib Sensitive : C3	sorafenib + gilteritinib Sensitive: C3 – Early Trials sorafenib + gilteritinib Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3	ARO-002 Sensitive: C3 – Early Trials ARO-002 Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3 inhibitor Sensitive: C3 – Early Trials FLT3 inhibitor Sensitive : C3	FLT3 inhibitor Sensitive: C3 – Early Trials FLT3 inhibitor Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3	midostaurin + gemtuzumab ozogamicin Sensitive: C3 – Early Trials midostaurin + gemtuzumab ozogamicin Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	HEC73543 Sensitive: C3 – Early Trials HEC73543 Sensitive : C3	HEC73543 Sensitive: C3 – Early Trials HEC73543 Sensitive : C3
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	JRF104 Sensitive: D – Preclinical JRF104 Sensitive : D	JRF104 Sensitive: D – Preclinical JRF104 Sensitive : D
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D	PHI-101 Sensitive: D – Preclinical PHI-101 Sensitive : D